Clinical Trial Update: RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update comparing RO7771950 versus tucatinib, each in combination with trastuzumab and capecitabine, for HER2-positive breast cancer (locally adva…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• RO7771950
• Trastuzumab (trastuzumab)
• Tucatinib (tucatinib)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: HER2-positive Breast Cancer | Phase 2, Phase 3 | Status: NOT_YET_RECRUITING